BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 21451152)

  • 1. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy.
    French JA; Abou-Khalil BW; Leroy RF; Yacubian EM; Shin P; Hall S; Mansbach H; Nohria V;
    Neurology; 2011 May; 76(18):1555-63. PubMed ID: 21451152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy.
    Brodie MJ; Lerche H; Gil-Nagel A; Elger C; Hall S; Shin P; Nohria V; Mansbach H;
    Neurology; 2010 Nov; 75(20):1817-24. PubMed ID: 20944074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retigabine as adjunctive therapy in adults with partial-onset seizures: integrated analysis of three pivotal controlled trials.
    Porter RJ; Burdette DE; Gil-Nagel A; Hall ST; White R; Shaikh S; DeRossett SE
    Epilepsy Res; 2012 Aug; 101(1-2):103-12. PubMed ID: 22512894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of retigabine/ezogabine as adjunctive therapy in adult Asian patients with drug-resistant partial-onset seizures: A randomized, placebo-controlled Phase III study.
    Lim KS; Lotay N; White R; Kwan P
    Epilepsy Behav; 2016 Aug; 61():224-230. PubMed ID: 27376872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of different titration rates of retigabine (ezogabine) in patients with partial-onset seizures.
    Biton V; Gil-Nagel A; Brodie MJ; Derossett SE; Nohria V
    Epilepsy Res; 2013 Nov; 107(1-2):138-45. PubMed ID: 24094693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability exposure-response relationship of retigabine (ezogabine) immediate-release tablets in patients with partial-onset seizures.
    Tompson DJ; Crean CS; Reeve R; Berry NS
    Clin Ther; 2013 Aug; 35(8):1174-1185.e4. PubMed ID: 23916044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures.
    Porter RJ; Partiot A; Sachdeo R; Nohria V; Alves WM;
    Neurology; 2007 Apr; 68(15):1197-204. PubMed ID: 17420403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures.
    Lerche H; Daniluk J; Lotay N; DeRossett S; Edwards S; Brandt C
    Seizure; 2015 Aug; 30():93-100. PubMed ID: 26216692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel design for a dose finding, safety, and drug interaction study of an antiepileptic drug (retigabine) in early clinical development.
    Sachdeo R; Partiot A; Biton V; Rosenfeld WE; Nohria V; Tompson D; DeRossett S; Porter RJ
    Int J Clin Pharmacol Ther; 2014 Jun; 52(6):509-18. PubMed ID: 24755135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels.
    Brickel N; Gandhi P; VanLandingham K; Hammond J; DeRossett S
    Epilepsia; 2012 Apr; 53(4):606-12. PubMed ID: 22428574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial.
    Biton V; Berkovic SF; Abou-Khalil B; Sperling MR; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):57-66. PubMed ID: 24446953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: implications for clinical use.
    Large CH; Sokal DM; Nehlig A; Gunthorpe MJ; Sankar R; Crean CS; Vanlandingham KE; White HS
    Epilepsia; 2012 Mar; 53(3):425-36. PubMed ID: 22221318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of ethanol on the pharmacokinetics, pharmacodynamics, safety, and tolerability of ezogabine (retigabine).
    Crean CS; Tompson DJ
    Clin Ther; 2013 Jan; 35(1):87-93. PubMed ID: 23328270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.
    Ryvlin P; Werhahn KJ; Blaszczyk B; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):47-56. PubMed ID: 24256083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.
    French JA; Krauss GL; Steinhoff BJ; Squillacote D; Yang H; Kumar D; Laurenza A
    Epilepsia; 2013 Jan; 54(1):117-25. PubMed ID: 22905857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures.
    Wu XY; Hong Z; Wu X; Wu LW; Wang XF; Zhou D; Zhao ZX; Lv CZ
    Epilepsia; 2009 Mar; 50(3):398-405. PubMed ID: 18657175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
    Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA
    Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy.
    Gunthorpe MJ; Large CH; Sankar R
    Epilepsia; 2012 Mar; 53(3):412-24. PubMed ID: 22220513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, controlled, dose-ranging trial of carisbamate for partial-onset seizures.
    Faught E; Holmes GL; Rosenfeld WE; Novak G; Neto W; Greenspan A; Schmitt J; Yuen E; Reines S; Haas M
    Neurology; 2008 Nov; 71(20):1586-93. PubMed ID: 19001248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retigabine for partial onset seizures.
    Rheims S; Ryvlin P
    Expert Rev Neurother; 2012 May; 12(5):509-17. PubMed ID: 22550979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.